157 filings
Page 3 of 8
6-K
ibv7r8fktm rmv
17 Feb 23
Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15
5:30pm
6-K
83qgabb y2bstt
16 Feb 23
Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate
8:33am
6-K
y6aok
3 Jan 23
Valneva Reports Further Heterologous Booster Data for its inactivated COVID-19 vaccine
11:33am
6-K
skmi slk6y6qa
23 Dec 22
Valneva to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference and Oddo BHF Forum
8:21am
6-K
jvlxr cciag9ahx27
6 Dec 22
Valneva Reports Positive 12-Month Antibody Persistence Data for Single-Shot Chikungunya Vaccine Candidate
5:30pm
6-K
1r4id4e
1 Dec 22
Valneva to Host Investor Day in New York City
6:05am
6-K
rbep5qqx
17 Nov 22
Valneva Appoints Dipal Patel as Chief Commercial Officer
2:05pm
6-K
xijy6f
10 Nov 22
Valneva Reports Nine-Month 2022 Results and Provides Corporate Updates
11:05am
6-K
s8hwnds2
8 Nov 22
Valneva to Present and Hold Investor Meetings at the Jefferies London Healthcare Conference
10:48am
6-K
9o7bh3subju
11 Oct 22
Valneva to Present on its Single-Shot Chikungunya Vaccine Candidate at Leading Scientific Conferences
12:37pm
6-K
xcztz9rpd6t 8aj
6 Oct 22
Valneva Announces Closing of Upsized €102.9 Million Global Offering
6:02am
6-K
8fub1e8g e7
30 Sep 22
Valneva Announces the Pricing of €102.9 Million Global Offering of American Depositary Shares and Ordinary Shares
4:22pm
424B5
z736omk c9k9ko4
30 Sep 22
Prospectus supplement for primary offering
4:09pm
6-K
1msjg sj4q
29 Sep 22
Valneva Announces Launch of Approximately $40 Million in a Proposed Global Offering of American Depositary Shares and Ordinary Shares
7:36am
424B5
8ay2kxprybmg4klg ir
28 Sep 22
Prospectus supplement for primary offering
8:24pm
6-K
uav1qiir3wnxmz0
26 Sep 22
Valneva Provides Further Update on its COVID-19 Activities
4:30pm
6-K
eqodramwtntq
20 Sep 22
Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration
1:00pm
6-K
bzueqlx ezm81034baq
8 Sep 22
Valneva Announces Publication of its COVID-19 Vaccine Phase 3 Data in The Lancet Infectious Diseases
3:39pm
6-K
gdpx po4vcw1
29 Aug 22
Current report (foreign)
5:00pm
6-K
csv1tb
26 Aug 22
Valneva Confirms WHO Recommendations for its Inactivated COVID-19 Vaccine
5:00pm